Cipla
Respiratory-led franchise with a strong India brand portfolio, US inhalation/peptide complex generics (gAdvair, gAbraxane) and a meaningful emerging-markets/SAGA presence.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
India branded (One-India), US respiratory & peptide complex generics, South Africa, API.
US peptide/respiratory complex launches + India chronic
US plant (Goa/Indore) regulatory overhang
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Cipla | 7% | 26% | 23% | 29x |
| Sun Pharmaceutical Industries | 22% | 29% | 20.5% | 35x |
| Dr. Reddy's Laboratories | 4% | 26% | 13.6% | 25x |
| Lupin | 25% | 23% | 30.3% | 18x |
| Torrent Pharmaceuticals | 25% | 32% | 27% | 68x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • US peptide/respiratory complex launches + India chronic underpins a 7% 5Y revenue CAGR.
- • Premium 26% EBITDA margin with 23% ROCE signals durable economics.
- • Clean balance sheet (D/E 0.05) funds growth internally.
- • US plant (Goa/Indore) regulatory overhang.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Re-rating depends on proving R&D/return discipline.
Cipla screens as a high-quality diversified franchise. With revenue of ₹27.5K Cr growing ~7% and 26% EBITDA margins, the base case is steady compounding driven by us peptide/respiratory complex launches + india chronic, while watching us plant (goa/indore) regulatory overhang.
Trades at 29x P/E, 15.0x EV/EBITDA and 3.2x P/B. Reasonable versus growth — re-rating optionality if execution improves.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
Mix approximated from Q4FY25 (One India, North America, One Africa/SA, EMs/Europe→RoW). ANDA counts not cleanly disclosed.